Abstract:
:Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for patients with AML was limited to induction chemotherapy with cytarabine and anthracycline or hypomethylating agents, and, in some instances, allogeneic hematopoietic stem cell transplant. With the recent approval of new therapies-i.e., CPX-351, enasidenib, ivosidenib, gemtuzumab ozogamicin, and midostaurin-a new era in AML treatment has emerged. Comprehensive diagnostic testing, such as cytogenetic and molecular testing, is necessary for establishing patient eligibility for these new agents and should be performed in a timely manner. However, choosing a therapy for patients who are eligible for multiple treatments may be a complex process, particularly for patients with newly diagnosed AML. This review discusses data, including associated safety profiles that supported these recent approvals, and provides insights to help clinicians navigate new therapy options for this devastating disease. Given the heterogeneity of AML, the treatment landscape will likely continue to grow and evolve as additional agents (and their combinations) are approved for the treatment of subpopulations of patients with AML. Physicians will need to remain abreast of the ever-changing treatment landscape.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Talati C,Sweet Kdoi
10.1016/j.leukres.2018.09.001subject
Has Abstractpub_date
2018-10-01 00:00:00pages
58-66eissn
0145-2126issn
1873-5835pii
S0145-2126(18)30207-8journal_volume
73pub_type
杂志文章,评审abstract::We investigated the transcript levels of genes STAT1, STAT3, STAT5A and STAT5B in the diagnostic samples of childhood ALL patients and compared them to those of healthy controls in order to characterize STAT gene expression in childhood ALL. As compared to controls, ALL patients exhibit markedly decreased transcript l...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.09.004
更新日期:2015-09-11 00:00:00
abstract::Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.12.008
更新日期:2010-08-01 00:00:00
abstract::Ras proteins are frequently over-expressed in leukemia and contribute to leukemogenesis. We evaluated the anti-leukemic efficacy of a new third-generation bisphosphonate, ONO5920/YM529 (YM529). YM529 prevents the prenylation of Ras proteins and inhibited the growth of leukemic cells including a P-glycoprotein (P-gp) o...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2004.10.004
更新日期:2005-04-01 00:00:00
abstract::Medullary dyserythropoiesis with reduced production of erythrocytes is an early and consistent feature of myelodysplastic syndromes (MDS). The mechanism underlying the disturbed red cell proliferation and maturation is presently unknown. In order to study the role of erythropoietic growth factors, we determined by rad...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90025-o
更新日期:1991-01-01 00:00:00
abstract::A wide range of different agents are capable of inducing the onset of HL-60 differentiation along the myeloid lineage. The diversity of these agents has made the analysis of the molecular mechanisms involved in the regulation of the onset and progress of terminal differentiation in these cells difficult. We have adapt...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(89)90081-7
更新日期:1989-01-01 00:00:00
abstract::The pre-B lymphoma in SL/Kh mice is a polygenic trait involving a number of host genes. In prelymphoma-stage bone marrow, transient pre-B cell expansion is induced by a host locus, Bomb1, and later followed by the emergence of a monoclonal population with a similar phenotype. To determine whether these pre-B cells rep...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2007.05.013
更新日期:2008-02-01 00:00:00
abstract:PURPOSE:The study aims to develop a prognostic scoring system based on prognostic lncRNAs for acute myeloid leukemia (AML). METHODS:Based on lncRNA expression profiles downloaded from The Cancer Genome Atlas (TCGA), differentially expressed long noncoding RNAs (DELs) between good prognosis and bad prognosis samples we...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2019.106261
更新日期:2020-01-01 00:00:00
abstract::We reported the different clinical features between Japanese and German refractory anemia (RA) patients in FAB classification. We re-analyzed the clinical features by WHO classification revised in 2008. The frequencies of refractory cytopenia with unilineage dysplasia (RCUD) and myelodysplastic syndrome-unclassified (...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.11.015
更新日期:2010-08-01 00:00:00
abstract::We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS). Retrospective analysis of a cryoprese...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(01)00140-0
更新日期:2002-04-01 00:00:00
abstract::Aggressive chemotherapy of myelodysplastic syndromes is rarely feasible because these disorders predominantly occur in elderly patients who often have concurrent illnesses. Alternative treatment modalities must therefore be evaluated. This review summarizes the results that have been obtained with low-dose chemotherap...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/0145-2126(92)90058-f
更新日期:1992-01-01 00:00:00
abstract::Using a short term liquid system we have shown that blood from some patients with primary myelofibrosis (PMF) and chronic granulocytic leukaemia (CGL) in megakaryoblastic transformation (CGL-Mk) gives rise to large numbers of progenitor cells committed to the megakaryocyte (Mk) lineage. As assessed by indirect immunof...
journal_title:Leukemia research
pub_type: 历史文章,杂志文章
doi:10.1016/0145-2126(85)90108-0
更新日期:1985-01-01 00:00:00
abstract::C3H/He mice produce myeloid leukemias after whole body irradiation of 1-3Gy as compared with non-irradiated controls that produce fewer than 1% of leukemia [Radiatiton Research 127 (1991) 146]. Thus, p53-deficient C57BL/6 strain, a malignant lymphoma prone, was crossed back into C3H/He strain. Lethally irradiated wild...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(02)00032-2
更新日期:2002-12-01 00:00:00
abstract::Fifty-three patients with Ph positive chronic myeloid leukaemia in blastic phase were studied. Additional abnormalities were found in 29 (55%) patients and were more common in myeloid (64%) than lymphoid (45%) blast crisis. The most frequent were +Ph (32%), +8 (28%), +19 (19%), +20 (9%) and +21 (9%). i(17q) (9%) was a...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(94)90023-x
更新日期:1994-05-01 00:00:00
abstract::The acid phosphatase (AP), beta-glucuronidase (BG), and alpha-naphthyl-acetate esterase (ANAE) distribution and the morphology of stage 0 B-CLL lymphocytes were studied. The results were compared with the same hydrolase equipment and morphology of normal B-cell populations showing the B-CLL-like phenotype, and thus re...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(87)90074-9
更新日期:1987-01-01 00:00:00
abstract::The monoclonal antibody AGF2.3 identifies a nuclear envelope protein expressed at high levels in most transformed cell lines and weakly expressed in or absent from normal tissues and primary cell cultures. Here we report that expression of AGF2.3 antigen relates to the maturation status of cells. When HL60 cells were ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(86)90235-3
更新日期:1986-01-01 00:00:00
abstract::Activating mutations of Fms-like tyrosine kinase 3 (Flt3) are the most common genetic abnormalities found in acute myeloid leukemia (AML) and represent potential therapeutic targets. The novel Flt3 inhibitor KRN383 inhibited the autophosphorylation of Flt3 bearing internal tandem duplications (ITDs) and the Asp835Tyr ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.02.028
更新日期:2006-12-01 00:00:00
abstract:OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.04.006
更新日期:2009-12-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:A consecutive series of acute myeloid leukemias (AML) patients was analyzed in conditions which reduce the inter-assay variations (the same flow cytometer, the same observers and the same panel of monoclonal antibodies) in order to investigate the prognostic information provided by flow cytome...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2005.02.015
更新日期:2005-10-01 00:00:00
abstract::To clarify whether expression of the programmed cell death 5 (PDCD5) gene in leukemic cells is abnormal, real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) was used to examine its expression in marrow cells from leukemia patients. We found lower PDCD5 in both AML and CML marrow cells th...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.12.028
更新日期:2006-09-01 00:00:00
abstract::Among 17,633 U.S. white male insurance policy holders whose use of tobacco was characterized in a 1966 self-administered questionnaire, there were 49 deaths from non-Hodgkin's lymphoma (NHL) and 21 from multiple myeloma (MM) during a 20-year follow-up. Men who had ever smoked cigarettes had an elevated mortality from ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90011-u
更新日期:1992-06-01 00:00:00
abstract::We investigated Syk as a potential marker of CML progression. We observed a significant over-expression of Syk mRNA and constitutive phosphorylation of Syk Y348 in blast cells from six AP or BP-CML, but not in 15 CML in chronic phase. We could follow in vivo the recurrence of pSyk(348) throughout blast cell escape, de...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2014.11.014
更新日期:2015-03-01 00:00:00
abstract::The technology of array comparative genomic hybridization (array-CGH/aCGH) enabled the identification of novel genomic aberrations in chronic lymphocytic leukemia (CLL) including the monoallelic and biallelic deletions affecting 22q11 locus. In contrast to previous publications, we hypothesized that the described 22q1...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.03.018
更新日期:2013-07-01 00:00:00
abstract::The remarkable capacity of the bone marrow to compensate for blood loss and for reduced atmospheric oxygen tension has been found to be mediated by a renal hormone, named erythropoietin. It is produced by peritubular interstitial cells in response to renal hypoxia, but molecular engineering has permitted large scale p...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/0145-2126(90)90094-p
更新日期:1990-01-01 00:00:00
abstract::We used fluorescence in situ hybridization (FISH) assays to identify t(14;18) translocations in archival paraffin-embedded tumor sections from non-Hodgkin lymphoma (NHL) cases enrolled in a population-based study. t(14;18) was identified in 54% of 152 cases, including 39% of diffuse large cell lymphomas (26 of 66 case...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.05.007
更新日期:2010-02-01 00:00:00
abstract::Ml cells were labeled in vitro with [3H]thymidine and injected into the peritoneal cavity of syngeneic mice. After several days the peritoneal cells were harvested and [3H]labeled cells were determined by autoradiography. The inoculated isotope-labeled Ml cells differentiated in the peritoneal cavity and lipopolysacch...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(82)90050-9
更新日期:1982-01-01 00:00:00
abstract::In a prospective study of 27 patients with acute myeloid leukaemia (AML) quality of life was studied using three different instruments, Life Ingredient Profile, Karnofsky Performance Scale and Vitagram. The course of the disease was followed during the induction period, remission, relapse and in the terminal phase. We...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(94)90028-0
更新日期:1994-04-01 00:00:00
abstract::Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.03.015
更新日期:2015-07-01 00:00:00
abstract::Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few nor...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.03.007
更新日期:2008-10-01 00:00:00
abstract::Pro-apoptotic signalling upon toll-like receptor (TLR) stimulation in myeloid cells is normally antagonized by the simultaneous activation of anti-apoptotic pathways. We have previously reported that IFN-alpha can sensitize human monocytes to apoptosis induction by lipopolysaccharide (LPS). Based on these results we i...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2007.05.001
更新日期:2007-12-01 00:00:00
abstract::We have earlier shown that VP-16 combined with Cyclosporin A (CsA) produces tumor specific immunity to L1210 leukemia in BDF/1 mice [Slater LM, Sweet P, Stupecky M, Reynolds JT. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD(8) T-lymphocytes, Clin Immunol Immunopathol 1995;7...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(01)00105-9
更新日期:2002-02-01 00:00:00